Research and development

Daiichi Sankyo is dynamically moving ahead with efforts to overcome challenges associated with unmet medical needs.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Such medical problems as thrombotic disorders and malignant neoplasm are two therapeutic areas that face a high level of unmet medical needs. Patients and healthcare professionals are eagerly awaiting new pharmaceutical solutions.
In such core disease areas, the company is proactively obtaining advanced technologies and pipeline candidates from outside sources, and it made particularly good progress in augmenting its development pipeline in the cancer area during the past year.